Bristol Myers Squibb CELG-RI
NYSE CELG-RI
$0.12 +0.02 (+17.65%)
As of: Aug 21, 2026 · 2:40 PM EDT

Bristol Myers Squibb (CELG-RI) Curent Deferred Tax Liability (2009 - 2012)

Bristol Myers Squibb (CELG-RI) posted quarterly Curent Deferred Tax Liability of -$10.0 million for Q4 2012, down 66.67% year-over-year from -$30.0 million in Q1 2012, and down 66.67% quarter-over-quarter from -$6.0 million in Q4 2011.

Bristol Myers Squibb (CELG-RI) Curent Deferred Tax Liability (2009 - 2012) Analysis & Trends

Bristol Myers Squibb (CELG-RI) has reported Curent Deferred Tax Liability for 4 consecutive years, with -$10.0 million the latest figure, recorded in Q4 2012.

  • In Q4 2012, Curent Deferred Tax Liability fell 66.67% year-over-year to -$10.0 million; the TTM figure through Dec 2012 stood at -$10.0 million (down 66.67% YoY), while the FY2012 annual figure was -$10.0 million, down 66.67% from the prior year.
  • Curent Deferred Tax Liability fell to -$10.0 million in Q4 2012 per CELG-RI's latest filing, from -$6.0 million in the prior quarter.
  • Across five years, Curent Deferred Tax Liability topped out at $8.0 million in Q4 2009 and bottomed at -$10.0 million in Q4 2012.
  • Historically, Curent Deferred Tax Liability has averaged -$3.2 million across 4 years, with a median of -$5.5 million in 2010.
  • Annual changes were most pronounced in 2010 — Curent Deferred Tax Liability plunged 162.5% — and 2011, when it dropped 20.0%.
  • Bristol Myers Squibb's Curent Deferred Tax Liability stood at $8.0 million in 2009, then slumped by 162.5% to -$5.0 million in 2010, then slipped by 20.0% to -$6.0 million in 2011, then slumped by 66.67% to -$10.0 million in 2012.
  • Business Quant data shows CELG-RI's Curent Deferred Tax Liability at -$10.0 million in Q4 2012, -$6.0 million in Q4 2011, and -$5.0 million in Q4 2010.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Curent Deferred Tax Liability (Qtr)
1 Johnson & Johnson 652.20 Bn 631.44 Bn 17.26 Bn -
2 AbbVie 469.51 Bn 462.94 Bn 12.70 Bn -
3 Merck 376.81 Bn 369.67 Bn 12.21 Bn -
4 Novartis Ag 303.04 Bn 295.35 Bn 11.24 Bn -
5 Astrazeneca 257.61 Bn 252.71 Bn 12.86 Bn -
6 Amgen 237.37 Bn 223.38 Bn 7.24 Bn -
7 Gilead Sciences 181.73 Bn 178.55 Bn 6.22 Bn -
8 Pfizer 159.66 Bn 147.96 Bn 10.94 Bn -
9 Gsk 106.24 Bn 102.07 Bn 8.24 Bn -
10 Bristol Myers Squibb 224.21 Mn -10.84 Bn 9.25 Bn -

Historic Data

Download Data
DateValue
Dec 31, 2012 -10.00 Mn
Dec 31, 2012 -10.00 Mn
Dec 31, 2011 -6.00 Mn
Dec 31, 2011 -6.00 Mn
Dec 31, 2010 -5.00 Mn
Dec 31, 2010 -5.00 Mn
Dec 31, 2009 8.00 Mn
Dec 31, 2009 8.00 Mn